Day: April 29, 2021

Achiko AG’s Joint Venture Partner PT Indonesia Farma Medis (IFM) Obtains Medical Device Distribution CertificateAchiko Subsequently Commenced Product Registration with its Partners with a View to Mid-Year Commercial Product AvailabilityAchiko to Generate Revenues on a 50% Holding of the Joint Venture and a 10% Licensing Fee from Gross SalesZURICH, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) — Achiko AG’s (SWX:ACHI, ISIN CH0522213468) joint venture partner PT Indonesia Farma Medis (“IFM”) has been granted a medical device distribution certificate for Indonesia and commences product registration for AptameX. This certificate will allow for the procurement, storage and distribution of the novel diagnostic test, AptameX (formerly Project Gumnuts) in Indonesia. It establishes the foundation for a subsequent product registration...

SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2021 financial results after the close of U.S. financial markets on Thursday, May 6, 2021. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (888) 771-4371 for domestic callers and (847) 585-4405 for international callers and entering the conference code: 50156205. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.        About...

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its first quarter 2021 financial results and operational highlights in a conference call on May 6 at 8 a.m. E.T. To join the call:U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.A replay of the call will be available through the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com, beginning on May 6 at 12 p.m. E.T. About Intellia TherapeuticsIntellia...

TROY, Mich., April 29, 2021 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA) (Nasdaq: KELYB), a leading specialty talent solutions provider, will release its first quarter earnings before the market opens on Thursday, May 13, 2021. In conjunction with its first quarter earnings release, Kelly will publish a financial presentation on the Investor Relations page of its public website and will host a conference call at 9 a.m. ET. The call may be accessed in one of the following ways: Via the Internet:Kellyservices.com Via the Telephone: (877) 692-8955 (toll free) or (234) 720-6979 (caller paid)Enter access code 5728672After the prompt, please enter “#” A recording of the conference call will be available after 2:30 p.m. ET on May 13, 2021 at (866) 207-1041 (toll-free) and (402) 970-0847 (caller-paid). The access code is 2456495#. The recording...

(All dollar amounts are expressed in U.S. dollars, unless otherwise noted.) TORONTO, April 29, 2021 (GLOBE NEWSWIRE) — Kinross Gold Corporation (TSX:K; NYSE:KGC) (“Kinross”) announced today it will redeem all of the outstanding 5.125% Senior Notes due September 1, 2021 (the “Notes”), which have an aggregate principal amount of $500 million, on June 1, 2021 (the “Redemption Date”). The Notes will be redeemed at a redemption price equal to the principal amount of the outstanding Notes plus accrued and unpaid interest to, but not including, the Redemption Date, in accordance with the terms of the Notes. Interest on the Notes will cease to accrue from and after the Redemption Date. After the Notes are redeemed, $1,250 million in aggregate principal amount of Kinross Senior Notes will remain outstanding, with the next maturity date...

MONTREAL, April 29, 2021 (GLOBE NEWSWIRE) — Dynacor Gold Mines Inc. (TSX: DNG / OTC: DNGDF) (Dynacor or the Corporation) is pleased to announce that the Toronto Stock Exchange (TSX) has approved the Corporation’s request to renew a normal course issuer bid (NCIB) program, through which Dynacor may purchase, for cancellation, up to 3,111,165 common shares or approximately 10% of the public float (31,111,651 common shares as of April 20, 2021). Dynacor is in a financially strong position to continue to return a portion of its cash to its shareholders through the NCIB. Additionally, it is reviewing other value-added opportunities which could further contribute to enhancing shareholder value. The Corporation may purchase shares under the NCIB over a period of twelve months commencing on May 3, 2021 and ending May 2, 2022, when...

First Quarter 2021 Revenues of $686.3 Million, Up 13.5% Compared to $604.6 Million in Prior Year Quarter First Quarter 2021 EPS of $1.84, Up 23.5% Compared to $1.49 in Prior Year Quarter; First Quarter 2021 Adjusted EPS of $1.89, Up 23.5% Compared to $1.53 in Prior Year QuarterWASHINGTON, April 29, 2021 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today released financial results for the quarter ended March 31, 2021. First quarter 2021 revenues of $686.3 million increased $81.7 million, or 13.5%, compared to revenues of $604.6 million in the prior year quarter. Excluding the estimated positive impact from foreign currency translation (“FX”), revenues increased $67.0 million, or 11.1%, compared to the prior year quarter. Acquisition-related revenues contributed $16.0 million in the quarter. Excluding the estimated...

– Peer-reviewed article in Journal of Bone and Mineral Research showed INZ-701 increased pyrophosphate (PPi) levels, improved disease markers, and decreased mortality in an ENPP1-deficient mouse model – – Preclinical findings support increase of PPi levels as a predictive marker of therapeutic benefit – BOSTON, April 29, 2021 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the online pre-publication release of preclinical data suggesting the potential of its lead development candidate, INZ-701, as a treatment for ENPP1 Deficiency. As reported in the Journal of Bone and Mineral Research (JBMR), in an article titled, “INZ‐701 prevents ectopic tissue calcification and restores bone...

HOUSTON, April 29, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today the titles of the abstracts accepted for poster presentations during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Salarius submitted three abstracts detailing research regarding seclidemstat, all of which have been accepted for poster presentations, with one abstract also selected for a poster discussion session. ASCO will be held virtually from June 4-8, 2021. The titles of the abstracts are currently available on ASCO’s 2021 Meeting Library with full abstracts, including the dates and times of presentations, scheduled for publication at 5 p.m. ET on May...

Strong Sales and Earnings despite challenging supply chain environment LISLE, Ill., April 29, 2021 (GLOBE NEWSWIRE) — CTS Corporation (NYSE: CTS) today announced first quarter 2021 results.Sales were $128.4 million, up 25% year-over-year. Sales to transportation customers increased 23%, and sales to other end markets grew 27%. The Sensor Scientific acquisition added $1.8 million of sales in the first quarter of 2021. Net earnings were $12.0 million or $0.37 per diluted share versus $3.8 million or $0.12 per diluted share in the first quarter of last year. Adjusted diluted EPS was $0.46, up from $0.19 in the first quarter of 2020. Free cash flow was $18.5 million, up from $7.4 million in the first quarter of 2020. New business wins were $156 million.“We achieved strong results in the quarter supported by robust customer demand....